Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5959520 | 0.89 | PPARD (0.53) | PPARDALDH1A1HPGDPPARGLMNA | |
| SCHEMBL5959429 | 0.89 | PPARD (0.48) | PPARDALDH1A1HPGDPPARGLMNA | |
| SCHEMBL5959743 | 0.88 | PPARD (0.53) | PPARDALDH1A1PPARGLMNASMN1; SMN2 | |
| SCHEMBL5959692 | 0.88 | PPARD (0.53) | PPARDALDH1A1PPARGLMNASMN1; SMN2 | |
| SCHEMBL5959493 | 0.88 | PPARD (0.50) | PPARDALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL5959765 | 0.88 | PPARD (0.50) | PPARDALDH1A1HPGDPPARGLMNA | |
| SCHEMBL5959605 | 0.87 | PPARD (0.68) | PPARDPPARGPPARA | |
| SCHEMBL5959714 | 0.87 | PPARD (0.53) | PPARDPPARGLMNAMAPTFFAR1 | |
| SCHEMBL5959550 | 0.87 | PPARD (0.48) | PPARDALDH1A1HPGDPPARGLMNA | |
| SCHEMBL5959430 | 0.86 | PPARD (0.67) | PPARDLMNAMAPTPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091245-B2 | Compounds, their preparation and use | NOVO NOVDISK A/S (DK) | 2006-08-15 | — | — | US | claimed |
| US-20040143006-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-22 | — | — | US | claimed |
| US-7091245-B2 | Compounds, their preparation and use | NOVO NOVDISK A/S (DK) | 2006-08-15 | — | — | US | disclosed |
| EP-1537076-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| US-20040143006-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-22 | — | — | US | disclosed |
| WO-2004022533-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143006-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885ALDH1A1 722/4885HPGD 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.